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Abstract
The kinetics of serum (1 ﬁ 3)-b-D-glucan (BG) following the diagnosis of invasive fungal disease and administration of antifungal therapy
are poorly characterized. It is unknown whether early BG changes have prognostic implications. We assessed the post-diagnostic kinet-
ics of BG in patients with an initial serum BG ‡80 pg/mL and at least one additional post-diagnostic BG value in the setting of invasive
aspergillosis (IA, n = 69), invasive candidiasis (IC, n = 40), or Pneumocystis jirovecii pneumonia (PCP, n = 18), treated with antifungal ther-
apy. Clinical failure of antifungal therapy and mortality were assessed at 6 and 12 weeks, and Cox modelling was used to assess the haz-
ard of initial BG and change in BG at 1 or 2 weeks for these outcomes. In patients with at least two BG values, median initial BG was
>500 pg/mL (interquartile range (IQR) 168 to >500; range 80 to >500) in IA, 136 pg/mL (IQR 88 to >500; range 31 to >500) in IC and
>500 pg/mL (IQR 235 to >500; range 86 to >500) in PCP. In patients with at least two BG values through to 1 week after diagnosis,
overall 1-week decline in BG was 0 pg/mL (IQR 0–53) in IA, 0 (IQR ) 65 to 12) in IC and 17 (IQR 0–82) in PCP. Most patients with
BG values through 6 and 12 weeks had persistent levels >80 pg/mL. Initial BG and the early trajectory of BG were not predictive of 6-
week or 12-week clinical failure or mortality. Whereas BG eventually declines in patients with IA, IC and PCP, it lacks prognostic value
within a clinically meaningful time frame.
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Background
Although the diagnostic performance of serum (1 ﬁ 3)-b-D-
glucan (BG) for invasive fungal disease (IFD) is fairly well-
deﬁned [1–4], its response to antifungal therapy is unknown.
In a murine invasive aspergillosis (IA) model, animals receiv-
ing antifungal therapy had lower BG levels at censoring than
untreated controls, and a decline in BG was associated with
improved survival [5,6]. In an analysis of its diagnostic perfor-
mance in a large cohort at our institution, BG sensitivity did
not decrease in patients treated with antifungal agents for
over a week, suggesting relatively slow BG clearance [4]. We
sought to determine whether BG declines within a clinically
meaningful timeframe with antifungal therapy, and whether
this decline has any prognostic value.
Methods
Patient population
We identiﬁed all Brigham and Women’s Hospital/Dana-Farber
Cancer Institute patients from January 2005 to June 2009 who
fulﬁlled the following criteria: (i) proven or probable IA or
invasive candidiasis (IC) per 2008 European Organization for
Research and Treatment of Cancer–Mycoses Study Group
(EORTC/MSG) IFD diagnostic criteria [7], independent of BG
results; or Pneumocystis jirovecii pneumonia (PCP) based on
host factors, a compatible clinical syndrome, and cysts in respi-
ratory tract specimens; (ii) BG ‡80 pg/mL at IFD diagnosis;
and (iii) receipt of antifungal therapy for IFD.
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Patients with concurrent invasive mycoses and patients
exposed to factors associated with elevated serum BG in the
absence of IFD, such as intravenous immunoglobulin, albumin
or cellulose haemodialysis membranes, were excluded [4,8].
No patients were bacteraemic with Pseudomonas aeruginosa,
Alcaligenes faecalis or Streptococcus pneumoniae; in vitro culture
supernatants of these organisms have been associated with
elevated BG levels [9].
Demographic, IFD and antifungal treatment details were
recorded. The IFD host factors were assessed using the cur-
rent EORTC/MSG deﬁnitions [7]. All BG values from IFD
diagnosis were recorded.
BG testing
Serum BG levels were determined with the Fungitell assay
(Associates of Cape Cod, East Falmouth, MA, USA) by a ref-
erence laboratory without knowledge of patient IFD status.
This assay is reported continuously for results between 31
and 500 pg/mL, and as >500 pg/mL for values above this
range. A value ‡80 pg/mL is considered positive. BG testing
was performed at the discretion of clinical care teams.
Outcome measures
Mortality and cause of death were assessed in all patients at
6 weeks, after which IFD-related mortality wanes [10], and
at 12 weeks, a secondary time point for IA and IC outcome
assessment that is recommended by the 2008 EORTC/MSG
therapeutic outcome consensus statement [11]. Patients
were further classiﬁed as clinical ‘successes’ (complete or
partial response) or clinical ‘failures’ (stable response, pro-
gression of disease, or death) at 6 and 12 weeks according
to these consensus criteria for deﬁning responses to antifun-
gal therapy [11]. There is some controversy about whether
to classify ‘stable response’ as clinical failure or success in
these consensus criteria, so we assessed the endpoint of ‘fail-
ure’ according to the standard deﬁnition and made a sepa-
rate assessment reclassifying the six stable response cases as
‘successes’ at 6 weeks.
Statistical methods
Change in BG at 1 and 2 weeks was calculated by linear
interpolation from the two surrounding data points in
patients with BG follow-up values extending through these
time points. For the purposes of this analysis, 501 pg/mL was
used for BG values reported as >500 pg/mL. Time to BG
<80 pg/mL was estimated using linear interpolation in
patients with values that eventually declined below this
threshold.
We used the Kaplan–Meier method to estimate clinical
failure of antifungal therapy (as a binary outcome) at 6 and
12 weeks and 6- and 12-week mortality. Cox modelling was
used to generate unadjusted hazard ratios (HRs) for initial
serum BG, change in BG after 1 and 2 weeks of antifungal
therapy, and other potential predictors of mortality or clini-
cal failure, including age, gender and IFD risk factors. Cox
modelling was also used to generate adjusted HRs for 6-
week and 12-week clinical failure and mortality.
All analyses were performed with STATA 10 (STATA,
College Station, TX, USA). The hospital’s Human Research
Committee approved this study.
Results
Invasive aspergillosis
We identiﬁed 88 patients with IA; 69 had at least two post-
diagnostic BG values and 53 had BG measurements at least
1 week after diagnosis. Key patient characteristics are out-
lined in Table 1.
Of 69 patients with at least two post-diagnostic BG values,
19 had proven IA and 50 had probable IA. One patient had
isolated sinus disease; the remaining 68 had pulmonary IA at
minimum, and six had multifocal IA. The causative Aspergillus
species was identiﬁed in 41 (59%) patients—32 A. fumigatus,
four A. ﬂavus, four A. terreus and one A. niger. Sixty-ﬁve (94%)
of 69 patients received voriconazole for treatment of IA dur-
ing their BG follow-up period. The remaining four patients
received amphotericin or echinocandin therapy.
Actuarial data on rates of patient mortality and failure to
respond to antifungal therapy at 6 and 12 weeks are pre-
sented in Table 2. Eleven patients who were alive at 6 weeks
had clinical outcomes that were discordant with their sur-
vival status—while alive, they were considered clinical fail-
ures because of either stable clinical response or evidence of
TABLE 1. Demographics and host factors in patients with at
least two (1 ﬁ 3)-b-D-glucan values
Invasive
aspergillosis,
n (%)
Invasive
candidiasis,
n (%)
Pneumocystis
jirovecii
pneumonia,
n (%)
n 69 40 18
Age, yearsa 54 (53–64;
19–79)
54 (42–63;
19–67)
53 (46–60;
23–82)
Female 29 (42) 12 (30) 9 (50)
Prolonged corticosteroidsb 33 (48) 6 (15) 6 (33)
T-cell
immunosuppressantsb
35 (51) 28 (70) 12 (67)
High-risk neutropeniab 24 (35) 18 (45) 0 (0)
Allogeneic HSCT 25 (36) 6 (15) 2 (11)
Grade III–IV acute
GVHD
4 (6) 0 (0) 0 (0)
aMedian, interquartile range, range.
bAs deﬁned by EORTC/MSG IFD diagnostic criteria [7].
HSCT, haematopoietic stem cell transplantation; GVHD: graft-versus-host dis-
ease.
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progressive infection. Only two patients with progressive dis-
ease had clinical outcomes that were discordant with their
survival status at 12 weeks.
Median initial BG was >500 pg/mL (interquartile range
(IQR) 169 to >500; range 80 to >500) overall and >500 pg/
mL (IQR 168 to >500; range 80 to >500) in patients with at
least two BG values. Patients with at least two BG values
had 3 values (IQR 2–6; range 2–20) following IA diagnosis
over 19 days (IQR 7–109; range 1–964).
In the 53 patients with BG values extending through
1 week after IA diagnosis, BG decline was 0 pg/mL (IQR 0–
53; range ) 347 to 160) at 1 week, with negative numbers
representing an increase in BG levels. Table 3 summarizes
changes in BG at 1 week by initial BG strata.
Twenty-seven patients had BG follow-up through to
6 weeks after IA diagnosis: 22 (82%) had persistent BG ele-
vation, with a median interpolated BG of 221 pg/mL (IQR
116 to >500; range <31 to >501). Twenty-two had concur-
rent galactomannan (GM) elevations at IA diagnosis; only
three (14%) patients had persistent GM >0.5 units at
6 weeks.
Twenty patients had BG follow-up 12 weeks after diagno-
sis; 12 (60%) had persistently elevated BG with a median
interpolated BG of 249 pg/mL (IQR 73 to >500; range <31
to >500). In contrast, 15 of these patients had concurrent
GM elevations at IA diagnosis; none had persistent GM ele-
vations >0.5 units at 12 weeks.
In 23 patients whose BG values eventually declined to
<80 pg/mL, median time to this threshold was 7 days (IQR
3–11; range 1–162) in 11 patients with an initial BG <150 pg/
mL, 17 days (IQR 10–24; range 4–76) in ﬁve patients with
initial BG 150–500 pg/mL, and 78 days (IQR 69–711; range
54–821) in seven patients with initial BG >500 pg/mL.
In nine lung transplant recipients with at least two BG val-
ues following IA diagnosis, ﬁve with pleural involvement,
median initial BG was >500 pg/mL (IQR >500 to >500; range
229 to >500). All eight patients with BG follow-up values
through to 6 weeks and seven patients with BG follow-up
through to 12 weeks had persistently elevated BG values.
One patient’s serum BG eventually declined to <80 pg/mL
2.6 years after IA diagnosis; the remaining six patients with
BG follow-up past 12 weeks had persistently elevated BG
values 0.4–1.8 years after diagnosis despite clinical IA resolu-
tion and in most patients, cessation of antifungal therapy.
In the whole cohort, initial BG was not predictive of 6-
week mortality, either in three strata, <150, 151–500 and
>500 pg/mL (HR 1.23; 95% CI 0.90–1.74), or continuously
(HR 1.11 per 100 pg/mL increase; 95% CI 0.95–1.28). In the
53 patients with BG values through at least 1 week after IA
diagnosis, change in BG at 1 week (HR 0.99 per 10 pg/mL
decline, 95% CI 0.95–1.04) or 2 weeks (HR 0.99 per 10 pg/
mL decline; 95% CI 0.92–1.06) was not predictive of 6-week
mortality, either alone or accounting for initial BG. Neither
initial BG nor change in BG at 1 or 2 weeks was predictive
of 12-week mortality, alone or adjusting for each other.
Initial BG did not predict clinical failure of antifungal ther-
apy at 6 weeks (HR 1.10 per 100 pg/mL increase; 95% CI
0.94–1.28) or 12 weeks (HR 1.12 per 100 pg/mL increase;
95% CI 0.95–1.31) in the cohort overall. In the 53 patients
with BG values at least 1 week following IA diagnosis, change
in BG at 1 week (HR 1.00 per 10 pg/mL decline; 95% CI
0.96–1.03) or 2 weeks (HR 1.00 per 10 pg/mL decline; 95%
CI 0.95–1.04) was not predictive of 6-week mortality, either
alone or accounting for initial BG. These HR estimates
remained unchanged when the six patients with a stable
response at 6 weeks were classiﬁed as clinical ‘successes’
TABLE 2. Clinical outcomes in patients with invasive asper-
gillosis at 6 and 12 weeks
6 weeks 12 weeks
All invasive aspergillosis patients (n = 88)
All-cause mortality (95% CI)a 0.51 (0.41–0.62) 0.60 (0.50–0.70)
Clinical failure in response to
antifungal therapy (95% CI)a,b
0.64 (0.54–0.74)c 0.62 (0.52–0.72)d
Patients with at least two (1 ﬁ 3)-b-D-glucan values (n = 69)
All-cause mortality (95% CI)a 0.38 (0.27–0.50) 0.49 (0.38–0.62)
Clinical failure in response to
antifungal therapy (95% CI)a,b
0.54 (0.42–0.66) 0.51 (0.40–0.63)
a95% CI: 95% conﬁdence interval.
bAs deﬁned by 2008 EORTC/MSG consensus criteria for deﬁning responses to
antifungal therapy.
cAt 6 weeks, 32 patients were considered clinical ‘successes’ (three complete
clinical responses, 29 partial responses) and 56 were considered clinical ‘failures’
(six stable responses, ﬁve progressive disease, and 45 deaths).
dAt 12 weeks, 34 patients were considered clinical ‘successes’ (13 complete clin-
ical responses, 21 partial responses) and 54 were considered clinical ‘failures’ (0
stable responses, two progressive disease, 52 deaths).
TABLE 3. Post-diagnostic kinetics
of (1 ﬁ 3)-b-D-glucan (BG) by ini-
tial BG strata in invasive aspergillo-
sis and invasive candidiasis patients
with at least two values 1 week
after a diagnosis of invasive fungal
disease
Invasive aspergillosis Invasive candidiasis
n BG decline, pg/mL (IQR, range)a n BG decline, pg/mL (IQR, range)a
All patients 53 0 (0–53; )347 to 160) 39 0 ()65 to 12; )365 to 243)
Initial BG <150 pg/mL 14 11 ()17 to 52; )129 to 75) 20 )37 ()92 to 3; )365 to 33)
Initial BG 150–500 pg/mL 14 38 ()293 to 104; )347 to 153) 7 18 (0–39; )264 to 243)
Initial BG >500 pg/mL 25 0 (0–0; 0–160) 12 0 (0–0; 0–127)
aNegative numbers indicate an interval increase in BG.
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rather than clinical ‘failures’. Neither initial BG nor change in
BG at 1 or 2 weeks was predictive of clinical failure in
response to antifungal therapy at 12 weeks, individually or
adjusting for each other. Excluding patients with non-linear
BG values (>500 pg/mL) within the ﬁrst 1–2 weeks, initial
BG and change in BG at 1 or 2 weeks were still not predic-
tive of 6-week or 12-week mortality or clinical failure, with
similar HRs.
Invasive candidiasis
We identiﬁed 75 patients with IC, 40 with at least two BG
values following IC diagnosis. Patient characteristics are out-
lined in Table 1.
Of patients with at least two post-diagnostic BG values,
36 had proven IC and four had probable IC. Of the 36 pro-
ven IC cases, 19 were caused by C. albicans, three by C. glab-
rata, three by C. tropicalis, two by C. parapsilosis, two by
C. krusei, one by C. guillermondii and one by Kodamaea (Pichia)
omeri. Three patients had concurrent candidaemia with more
than one species—C. albicans and C. tropicalis, C. albicans and
C. glabrata, and C. tropicalis and C. parapsilosis. Two patients
had abundant yeast forms and pseudohyphae strongly sugges-
tive of Candida species on visceral biopsy, with sterile biopsy
specimen cultures.
Twenty-eight patients with at least two BG values
received ﬂuconazole, eight received echinocandin and four
had voriconazole maintenance therapy for IC treatment dur-
ing their BG follow-up period.
All-cause mortality was 0.24 (95% CI 0.15–0.35) at
6 weeks and 0.28 (95% CI 0.19–0.40) at 12 weeks overall,
and 0.13 (95% CI 0.06–0.28) at 6 weeks and 0.21 (95% CI
0.11–0.37) at 12 weeks in the 40 patients with at least two
BG values. Clinical response at 6 and 12 weeks was concor-
dant with survival status in all IC patients—all patients had
either a complete or partial response or death at these time
points.
Median initial BG was 212 pg/mL (IQR 119 to >500; range
<31 to >500) overall and 136 pg/mL (IQR 88 to >500; range
31 to >500) in patients with at least two BG values. Patients
with at least two2 BG values had three values (IQR 2–5;
range 2–9) following IC diagnosis over 51 days (IQR 24–124;
range 4–832).
Median decline in BG 1 week after IC diagnosis was
0 pg/mL (IQR )65 to 12; range )365 to 243) in 39 patients
with BG follow-up extending through this time point.
Change in BG at 1 week by initial BG strata is summarized
in Table 3.
Sixteen (70%) of 23 patients with BG follow-up values
through 6 weeks had persistent BG elevations >80 pg/mL,
with a median 6-week interpolated BG of 138 pg/mL (IQR
82–489; range 47 to >501). Ten (63%) of 16 patients with
BG follow-up through 12 weeks had values >80 pg/mL, with
a median 12-week interpolated BG of 140 pg/mL (IQR 70–
428; range 31 to >500).
In the whole IC cohort, initial BG was not predictive of 6-
week mortality or clinical outcome (HR 0.87 per 100 pg/mL
increase; 95% CI 0.58–1.30). In the 40 patients with BG val-
ues through at least 1 or 2 weeks after IC diagnosis, change
in BG at 1 week (HR 1.00 per 10 pg/mL, 95% CI 0.96–1.05)
or 2 weeks (HR 0.99 per 10 pg/mL, 95% CI 0.95–1.04) was
also not predictive of 6-week mortality or clinical outcome,
either alone or accounting for initial BG. Initial BG and
change in BG at 1 or 2 weeks were also not predictive of
12-week mortality or clinical outcome, either alone or in
combination.
Pneumocystis jirovecii pneumonia
We identiﬁed 38 PCP patients, 18 with at least two post-
diagnostic BG values. Twenty-eight (74%) had an underlying
malignancy and seven (18%) were HIV positive. Of patients
with at least two BG values, 16 (89%) received trimetho-
prim–sulfamethoxazole, one received atovaquone and one
had primaquine and clindamycin for PCP treatment.
Median initial BG was >500 pg/mL (IQR 410 to >500;
range 86 to >500) overall and >500 pg/mL (IQR 235 to
>500; range 86 to >500) in patients with at least two BG val-
ues. Patients with at least two BG values had 2 values (IQR
2–3; range 2–11) over 22 days (IQR 15–115; range 1–347)
of BG follow-up. Median decline in BG was 17 pg/mL (IQR
0–82; range )343 to 205) 1 week after PCP diagnosis in 16
patients with BG follow-up through this time point.
Five of seven (71%) patients with BG values through to
6 weeks and four of six (67%) patients with BG follow-up
values through to 12 weeks after PCP diagnosis had BG val-
ues >80 pg/mL at these time points.
All-cause mortality was 0.22 (95% CI 0.11–0.39) at
6 weeks and 0.33 (95% CI 0.20–0.51) at 12 weeks in all
patients and 0.17 (95% CI 0.06–0.43) at 6 weeks and 0.28
(95% CI 0.13–0.54) at 12 weeks in patients with at least two
BG values. Clinical response at 6 and 12 weeks was perfectly
concordant with survival status in all PCP patients—all
patients had either a complete response or death at these
time points.
Neither initial BG (HR 1.05 per 100 pg/mL increase; 95%
CI 0.77–1.45) nor decline in BG at 1 week (HR 1.03 per
10 pg/mL, 95% CI 0.94–1.13) or 2 weeks (HR 1.00 per 10 pg/
mL, 95% CI 0.93–1.06) was predictive of 6-week mortality or
clinical outcome, alone or in combination. Neither initial BG
nor decline in BG at 1 or 2 weeks was predictive of 12-week
mortality or clinical outcome, alone or in combination.
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Discussion
Serum BG declined slowly in most IA, IC and PCP patients
treated with appropriate antifungal therapy, and often per-
sisted above the usual threshold for positivity long after clini-
cal resolution of the original infection. Neither BG height at
diagnosis nor early changes in BG levels were predictive of
clinical outcome or mortality at 6 or 12 weeks.
The rise and fall of serum BG remains poorly character-
ized in human IFD and probably depends on a range of
organism and host factors, including fungal species and bur-
den, location of the infection, structure and molecular
weights of BG released into the bloodstream, timeliness of
IFD diagnosis, host immune status, rate of glomerular ﬁltra-
tion of low-molecular-weight BG, and rate of hepatic degra-
dation of higher-molecular-weight BG [8,12,13].
In mammalian IA and PCP models, BG parallels fungal bur-
den and declines with effective therapy [5,6,14–16]. Data on
post-diagnostic BG kinetics in humans are sparse, but the
available data are concordant with our ﬁndings. One study of
BG for IA diagnosis in neutropenic patients with haematolog-
ical malignancies reported persistent BG elevations in
patients not responding to antifungal therapy and eventual
normalization in ﬁve IA patients who clinically responded to
antifungal therapy, although BG declined to <80 pg/mL after
6 weeks in patients whose values did eventually normalize
[17]. In six haematopoietic stem cell transplant recipients
with candidaemia, median time between clearance of candi-
daemia and decline of BG to less than the diagnostic thresh-
old for positivity was 48 days [18]. In 35 of 42 AIDS patients
with PCP, BG trajectory did not reﬂect the clinical course
after 3 weeks of therapy, and BG actually increased in nine
patients despite clinical improvement [19]. The authors
reported the eventual normalization of BG values several
months to years after treatment in all patients. In another
recent retrospective study of BG in 17 AIDS patients with
PCP, only three (18%) patients 4 weeks after PCP diagnosis
and seven (41%) patients 6 weeks after PCP diagnosis had
BG values less than the diagnostic threshold for positivity
[20].
It is unclear why BG appears to behave differently in
mammalian models compared with human infection—it may
reﬂect earlier initiation of antifungal therapy in experimental
models, before the onset of extensive invasive disease,
whereas in our cohort, BG testing was generally driven by a
syndrome suggestive of IFD.
There are major caveats to consider when interpreting
this study. Samples with values greater than the 500 pg/mL,
the upper threshold the Fungitell assay reports, were not
further characterized at the time of testing, and original
serum samples were unavailable for further analysis. We
were therefore unable to explore the full impact of the rate
of BG decay because of this artiﬁcial truncation of the assay’s
linear range, creating a ceiling effect. Initial BG and early BG
changes were not predictive of clinical outcome when we
restricted our analysis to values in the clinically reported lin-
ear range of the assay, and given the extremely slow clear-
ance of BG in patients with initial values >500 pg/mL, often
months to years after diagnosis, it is unlikely that these early
incremental changes in BG would have provided useful prog-
nostic information. Our study was also subject to the biases
of non-systematic testing, as BG values were obtained at the
discretion of the clinical care teams.
Post-diagnostic BG values have limited prognostic
value—BG often lingers in the serum past the clinical outcome
of interest, and its early trajectory does not appear to predict
clinical outcome. Unlike serum GM in IA [21], BG is not clearly
related to the hazard rate for mortality and does not capture
the net effects of IFD treatment on clinical outcome; it is
therefore unlikely to be a useful surrogate marker for success-
ful response to antifungal therapy in IFD patients [22,23].
Although BG has no discernible prognostic value, it probably
retains its use as an IFD diagnostic test even after initiation of
antifungal therapy, precisely because of its slow clearance.
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